Sigma-Aldrich (SIAL) Tops Q1 EPS by 58c

Sigma-Aldrich (NASDAQ: SIAL) reported Q1 EPS of $1.66, $0.58 better than the analyst estimate of $1.08. Revenue for the quarter came in at $676 million versus the consensus estimate of $685.23 million.

Commenting on performance in the first quarter of 2015, President and CEO Rakesh Sachdev said, "I am pleased to report that our teams delivered solid organic sales growth with contribution from all business units and major geographies. Despite a significant negative sales impact from unfavorable year-over-year changes in foreign currency exchange rates, the Company expanded adjusted operating margin and grew adjusted operating income.

Our Research business unit had growth contribution from all segments and geographies, continuing a trend that began in the second half of last year. Our Applied business unit was led by double-digit growth in the Diagnostics and Testing segment. Our SAFC Commercial business unit was led by the seventh consecutive quarter of double-digit organic sales growth in the Life Sciences Services segment and solid growth in the Life Sciences Product segment.

During the quarter, we launched new products such as the EX-CELL® Advanced CHO Fed-batch System, a high-performing batch media system developed for a range of widely used industrial CHO cell lines, including SAFC's proprietary CHOZN® cell line. We also launched Next-Gen Sequencing Oligos, which are adapters that improve target sequence assembly.

We officially opened our state-of-the-art dry powder media manufacturing facility in Irvine, Scotland, which now serves as the European counterpart to the Lenexa, Kansas, Center of Excellence for cell culture media manufacture and supply. In April, we opened our state-of-the-art Cell Culture Technical Center in Singapore to support our biopharmaceutical customers in this fast growing region.

In March, we announced an exclusive global distribution agreement with Roche. The agreement pairs Roche's Biochemical Reagents product portfolio, including kits and enzymes for cellular analysis, proteomics and conventional PCR applications, with Sigma-Aldrich's industry-leading eCommerce and supply chain capabilities."

Mr. Sachdev concluded, "Our teams are successfully executing the Company's growth initiatives, and we are excited about the opportunity to join forces with Merck KGaA of Darmstadt, Germany. We continue to expect the transaction to close in mid-2015, subject to receipt of certain antitrust and government approvals and other customary closing conditions."

For earnings history and earnings-related data on Sigma-Aldrich (SIAL) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• Live Oak Bancshares, Inc. (LOB) Misses Q1 EPS by 11c
• St. Joe Company (JOE) Reports Q1 EPS of $0.24